HomeCompareNARI vs MRK

NARI vs MRK: Dividend Comparison 2026

NARI yields 2.50% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $33.4K in total portfolio value
10 years
NARI
NARI
● Live price
2.50%
Share price
$79.97
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.4K
Annual income
$293.91
Full NARI calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — NARI vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNARIMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NARI + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NARI pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NARI
Annual income on $10K today (after 15% tax)
$212.58/yr
After 10yr DRIP, annual income (after tax)
$249.82/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $8,078.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NARI + MRK for your $10,000?

NARI: 50%MRK: 50%
100% MRK50/50100% NARI
Portfolio after 10yr
$40.1K
Annual income
$5,046.03/yr
Blended yield
12.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NARI
Analyst Ratings
4
Buy
8
Hold
Consensus: Hold
Price Target
$67.56
-15.5% upside vs current
Range: $50.00 — $86.00
Altman Z
11.2
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NARI buys
0
MRK buys
0
No recent congressional trades found for NARI or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNARIMRK
Forward yield2.50%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$23.4K$56.8K
Annual income after 10y$293.91$9,798.13
Total dividends collected$2.7K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$67.56$128.54

Year-by-year: NARI vs MRK ($10,000, DRIP)

YearNARI PortfolioNARI Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,950$250.09$11,206$366.19$256.00MRK
2$11,973$255.94$12,650$502.35$677.00MRK
3$13,072$261.53$14,407$694.19$1.3KMRK
4$14,254$266.87$16,585$967.82$2.3KMRK
5$15,524$271.96$19,342$1,363.89$3.8KMRK
6$16,887$276.81$22,913$1,947.19$6.0KMRK
7$18,351$281.42$27,662$2,823.89$9.3KMRK
8$19,921$285.81$34,159$4,173.35$14.2KMRK
9$21,606$289.97$43,337$6,308.80$21.7KMRK
10$23,412$293.91$56,776$9,798.13$33.4KMRK

NARI vs MRK: Complete Analysis 2026

NARIStock

Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

Full NARI Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this NARI vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NARI vs SCHDNARI vs JEPINARI vs ONARI vs KONARI vs MAINNARI vs JNJNARI vs ABBVNARI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.